Fetal cytomegalovirus infection
Cytomegalovirus (CMV) congenital infection affects 0.7% of live births worldwide and is the leading cause of congenital neurological handicap of infectious origin. However, systematic screening for this infection has not been implemented in pregnancy or at birth in any country. This apparent paradox...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Leruez-Ville, Marianne [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
11 |
|---|
| Übergeordnetes Werk: |
Enthalten in: In vitro and in vivo quality of bovine embryos in vitro produced with sex-sorted sperm - 2012transfer abstract, London [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:38 ; year:2017 ; pages:97-107 ; extent:11 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.bpobgyn.2016.10.005 |
|---|
| Katalog-ID: |
ELV040287688 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV040287688 | ||
| 003 | DE-627 | ||
| 005 | 20230625231424.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bpobgyn.2016.10.005 |2 doi | |
| 028 | 5 | 2 | |a GBVA2017004000002.pica |
| 035 | |a (DE-627)ELV040287688 | ||
| 035 | |a (ELSEVIER)S1521-6934(16)30109-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 590 |q VZ |
| 082 | 0 | 4 | |a 070 |a 004 |q VZ |
| 084 | |a LING |q DE-30 |2 fid | ||
| 084 | |a 54.00 |2 bkl | ||
| 084 | |a 53.71 |2 bkl | ||
| 100 | 1 | |a Leruez-Ville, Marianne |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fetal cytomegalovirus infection |
| 264 | 1 | |c 2017transfer abstract | |
| 300 | |a 11 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Cytomegalovirus (CMV) congenital infection affects 0.7% of live births worldwide and is the leading cause of congenital neurological handicap of infectious origin. However, systematic screening for this infection has not been implemented in pregnancy or at birth in any country. This apparent paradox had been justified by persisting gaps in the knowledge of this congenital infection: uncertain epidemiological data, difficulty in the diagnosis of maternal infection, absence of validated prenatal prognostic markers, unavailability of an efficient vaccine and scarcity of data available on the treatment. However, in the last decade, new data have emerged towards better management of this congenital infection, including solid epidemiological data, good evidence for the accuracy of diagnosis of maternal CMV infection and good evidence for the feasibility of predicting the outcome of fetal infection by a combination of fetal imaging and fetal laboratory parameters. There is also some evidence that valaciclovir treatment of mothers carrying an infected fetus is feasible, safe and might be effective. This review provides an update on the evidence for diagnosis, prognosis and treatment of congenital infection in the antenatal period. These suggest a benefit to a proactive approach for prenatal congenital infections. | ||
| 520 | |a Cytomegalovirus (CMV) congenital infection affects 0.7% of live births worldwide and is the leading cause of congenital neurological handicap of infectious origin. However, systematic screening for this infection has not been implemented in pregnancy or at birth in any country. This apparent paradox had been justified by persisting gaps in the knowledge of this congenital infection: uncertain epidemiological data, difficulty in the diagnosis of maternal infection, absence of validated prenatal prognostic markers, unavailability of an efficient vaccine and scarcity of data available on the treatment. However, in the last decade, new data have emerged towards better management of this congenital infection, including solid epidemiological data, good evidence for the accuracy of diagnosis of maternal CMV infection and good evidence for the feasibility of predicting the outcome of fetal infection by a combination of fetal imaging and fetal laboratory parameters. There is also some evidence that valaciclovir treatment of mothers carrying an infected fetus is feasible, safe and might be effective. This review provides an update on the evidence for diagnosis, prognosis and treatment of congenital infection in the antenatal period. These suggest a benefit to a proactive approach for prenatal congenital infections. | ||
| 650 | 7 | |a hyperimmune globulin |2 Elsevier | |
| 650 | 7 | |a valaciclovir |2 Elsevier | |
| 650 | 7 | |a cytomegalovirus |2 Elsevier | |
| 650 | 7 | |a serology |2 Elsevier | |
| 650 | 7 | |a imaging |2 Elsevier | |
| 650 | 7 | |a fetus |2 Elsevier | |
| 700 | 1 | |a Ville, Yves |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Harcourt |t In vitro and in vivo quality of bovine embryos in vitro produced with sex-sorted sperm |d 2012transfer abstract |g London [u.a.] |w (DE-627)ELV026204967 |
| 773 | 1 | 8 | |g volume:38 |g year:2017 |g pages:97-107 |g extent:11 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.bpobgyn.2016.10.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a FID-LING | ||
| 912 | |a SSG-OPC-BBI | ||
| 912 | |a GBV_ILN_50 | ||
| 912 | |a GBV_ILN_72 | ||
| 912 | |a GBV_ILN_1003 | ||
| 936 | b | k | |a 54.00 |j Informatik: Allgemeines |q VZ |
| 936 | b | k | |a 53.71 |j Theoretische Nachrichtentechnik |q VZ |
| 951 | |a AR | ||
| 952 | |d 38 |j 2017 |h 97-107 |g 11 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
m l v mlv |
|---|---|
| matchkey_str |
leruezvillemariannevilleyves:2017----:eactmglvrs |
| hierarchy_sort_str |
2017transfer abstract |
| bklnumber |
54.00 53.71 |
| publishDate |
2017 |
| allfields |
10.1016/j.bpobgyn.2016.10.005 doi GBVA2017004000002.pica (DE-627)ELV040287688 (ELSEVIER)S1521-6934(16)30109-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 590 VZ 070 004 VZ LING DE-30 fid 54.00 bkl 53.71 bkl Leruez-Ville, Marianne verfasserin aut Fetal cytomegalovirus infection 2017transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Cytomegalovirus (CMV) congenital infection affects 0.7% of live births worldwide and is the leading cause of congenital neurological handicap of infectious origin. However, systematic screening for this infection has not been implemented in pregnancy or at birth in any country. This apparent paradox had been justified by persisting gaps in the knowledge of this congenital infection: uncertain epidemiological data, difficulty in the diagnosis of maternal infection, absence of validated prenatal prognostic markers, unavailability of an efficient vaccine and scarcity of data available on the treatment. However, in the last decade, new data have emerged towards better management of this congenital infection, including solid epidemiological data, good evidence for the accuracy of diagnosis of maternal CMV infection and good evidence for the feasibility of predicting the outcome of fetal infection by a combination of fetal imaging and fetal laboratory parameters. There is also some evidence that valaciclovir treatment of mothers carrying an infected fetus is feasible, safe and might be effective. This review provides an update on the evidence for diagnosis, prognosis and treatment of congenital infection in the antenatal period. These suggest a benefit to a proactive approach for prenatal congenital infections. Cytomegalovirus (CMV) congenital infection affects 0.7% of live births worldwide and is the leading cause of congenital neurological handicap of infectious origin. However, systematic screening for this infection has not been implemented in pregnancy or at birth in any country. This apparent paradox had been justified by persisting gaps in the knowledge of this congenital infection: uncertain epidemiological data, difficulty in the diagnosis of maternal infection, absence of validated prenatal prognostic markers, unavailability of an efficient vaccine and scarcity of data available on the treatment. However, in the last decade, new data have emerged towards better management of this congenital infection, including solid epidemiological data, good evidence for the accuracy of diagnosis of maternal CMV infection and good evidence for the feasibility of predicting the outcome of fetal infection by a combination of fetal imaging and fetal laboratory parameters. There is also some evidence that valaciclovir treatment of mothers carrying an infected fetus is feasible, safe and might be effective. This review provides an update on the evidence for diagnosis, prognosis and treatment of congenital infection in the antenatal period. These suggest a benefit to a proactive approach for prenatal congenital infections. hyperimmune globulin Elsevier valaciclovir Elsevier cytomegalovirus Elsevier serology Elsevier imaging Elsevier fetus Elsevier Ville, Yves oth Enthalten in Harcourt In vitro and in vivo quality of bovine embryos in vitro produced with sex-sorted sperm 2012transfer abstract London [u.a.] (DE-627)ELV026204967 volume:38 year:2017 pages:97-107 extent:11 https://doi.org/10.1016/j.bpobgyn.2016.10.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-LING SSG-OPC-BBI GBV_ILN_50 GBV_ILN_72 GBV_ILN_1003 54.00 Informatik: Allgemeines VZ 53.71 Theoretische Nachrichtentechnik VZ AR 38 2017 97-107 11 045F 610 |
| spelling |
10.1016/j.bpobgyn.2016.10.005 doi GBVA2017004000002.pica (DE-627)ELV040287688 (ELSEVIER)S1521-6934(16)30109-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 590 VZ 070 004 VZ LING DE-30 fid 54.00 bkl 53.71 bkl Leruez-Ville, Marianne verfasserin aut Fetal cytomegalovirus infection 2017transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Cytomegalovirus (CMV) congenital infection affects 0.7% of live births worldwide and is the leading cause of congenital neurological handicap of infectious origin. However, systematic screening for this infection has not been implemented in pregnancy or at birth in any country. This apparent paradox had been justified by persisting gaps in the knowledge of this congenital infection: uncertain epidemiological data, difficulty in the diagnosis of maternal infection, absence of validated prenatal prognostic markers, unavailability of an efficient vaccine and scarcity of data available on the treatment. However, in the last decade, new data have emerged towards better management of this congenital infection, including solid epidemiological data, good evidence for the accuracy of diagnosis of maternal CMV infection and good evidence for the feasibility of predicting the outcome of fetal infection by a combination of fetal imaging and fetal laboratory parameters. There is also some evidence that valaciclovir treatment of mothers carrying an infected fetus is feasible, safe and might be effective. This review provides an update on the evidence for diagnosis, prognosis and treatment of congenital infection in the antenatal period. These suggest a benefit to a proactive approach for prenatal congenital infections. Cytomegalovirus (CMV) congenital infection affects 0.7% of live births worldwide and is the leading cause of congenital neurological handicap of infectious origin. However, systematic screening for this infection has not been implemented in pregnancy or at birth in any country. This apparent paradox had been justified by persisting gaps in the knowledge of this congenital infection: uncertain epidemiological data, difficulty in the diagnosis of maternal infection, absence of validated prenatal prognostic markers, unavailability of an efficient vaccine and scarcity of data available on the treatment. However, in the last decade, new data have emerged towards better management of this congenital infection, including solid epidemiological data, good evidence for the accuracy of diagnosis of maternal CMV infection and good evidence for the feasibility of predicting the outcome of fetal infection by a combination of fetal imaging and fetal laboratory parameters. There is also some evidence that valaciclovir treatment of mothers carrying an infected fetus is feasible, safe and might be effective. This review provides an update on the evidence for diagnosis, prognosis and treatment of congenital infection in the antenatal period. These suggest a benefit to a proactive approach for prenatal congenital infections. hyperimmune globulin Elsevier valaciclovir Elsevier cytomegalovirus Elsevier serology Elsevier imaging Elsevier fetus Elsevier Ville, Yves oth Enthalten in Harcourt In vitro and in vivo quality of bovine embryos in vitro produced with sex-sorted sperm 2012transfer abstract London [u.a.] (DE-627)ELV026204967 volume:38 year:2017 pages:97-107 extent:11 https://doi.org/10.1016/j.bpobgyn.2016.10.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-LING SSG-OPC-BBI GBV_ILN_50 GBV_ILN_72 GBV_ILN_1003 54.00 Informatik: Allgemeines VZ 53.71 Theoretische Nachrichtentechnik VZ AR 38 2017 97-107 11 045F 610 |
| allfields_unstemmed |
10.1016/j.bpobgyn.2016.10.005 doi GBVA2017004000002.pica (DE-627)ELV040287688 (ELSEVIER)S1521-6934(16)30109-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 590 VZ 070 004 VZ LING DE-30 fid 54.00 bkl 53.71 bkl Leruez-Ville, Marianne verfasserin aut Fetal cytomegalovirus infection 2017transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Cytomegalovirus (CMV) congenital infection affects 0.7% of live births worldwide and is the leading cause of congenital neurological handicap of infectious origin. However, systematic screening for this infection has not been implemented in pregnancy or at birth in any country. This apparent paradox had been justified by persisting gaps in the knowledge of this congenital infection: uncertain epidemiological data, difficulty in the diagnosis of maternal infection, absence of validated prenatal prognostic markers, unavailability of an efficient vaccine and scarcity of data available on the treatment. However, in the last decade, new data have emerged towards better management of this congenital infection, including solid epidemiological data, good evidence for the accuracy of diagnosis of maternal CMV infection and good evidence for the feasibility of predicting the outcome of fetal infection by a combination of fetal imaging and fetal laboratory parameters. There is also some evidence that valaciclovir treatment of mothers carrying an infected fetus is feasible, safe and might be effective. This review provides an update on the evidence for diagnosis, prognosis and treatment of congenital infection in the antenatal period. These suggest a benefit to a proactive approach for prenatal congenital infections. Cytomegalovirus (CMV) congenital infection affects 0.7% of live births worldwide and is the leading cause of congenital neurological handicap of infectious origin. However, systematic screening for this infection has not been implemented in pregnancy or at birth in any country. This apparent paradox had been justified by persisting gaps in the knowledge of this congenital infection: uncertain epidemiological data, difficulty in the diagnosis of maternal infection, absence of validated prenatal prognostic markers, unavailability of an efficient vaccine and scarcity of data available on the treatment. However, in the last decade, new data have emerged towards better management of this congenital infection, including solid epidemiological data, good evidence for the accuracy of diagnosis of maternal CMV infection and good evidence for the feasibility of predicting the outcome of fetal infection by a combination of fetal imaging and fetal laboratory parameters. There is also some evidence that valaciclovir treatment of mothers carrying an infected fetus is feasible, safe and might be effective. This review provides an update on the evidence for diagnosis, prognosis and treatment of congenital infection in the antenatal period. These suggest a benefit to a proactive approach for prenatal congenital infections. hyperimmune globulin Elsevier valaciclovir Elsevier cytomegalovirus Elsevier serology Elsevier imaging Elsevier fetus Elsevier Ville, Yves oth Enthalten in Harcourt In vitro and in vivo quality of bovine embryos in vitro produced with sex-sorted sperm 2012transfer abstract London [u.a.] (DE-627)ELV026204967 volume:38 year:2017 pages:97-107 extent:11 https://doi.org/10.1016/j.bpobgyn.2016.10.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-LING SSG-OPC-BBI GBV_ILN_50 GBV_ILN_72 GBV_ILN_1003 54.00 Informatik: Allgemeines VZ 53.71 Theoretische Nachrichtentechnik VZ AR 38 2017 97-107 11 045F 610 |
| allfieldsGer |
10.1016/j.bpobgyn.2016.10.005 doi GBVA2017004000002.pica (DE-627)ELV040287688 (ELSEVIER)S1521-6934(16)30109-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 590 VZ 070 004 VZ LING DE-30 fid 54.00 bkl 53.71 bkl Leruez-Ville, Marianne verfasserin aut Fetal cytomegalovirus infection 2017transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Cytomegalovirus (CMV) congenital infection affects 0.7% of live births worldwide and is the leading cause of congenital neurological handicap of infectious origin. However, systematic screening for this infection has not been implemented in pregnancy or at birth in any country. This apparent paradox had been justified by persisting gaps in the knowledge of this congenital infection: uncertain epidemiological data, difficulty in the diagnosis of maternal infection, absence of validated prenatal prognostic markers, unavailability of an efficient vaccine and scarcity of data available on the treatment. However, in the last decade, new data have emerged towards better management of this congenital infection, including solid epidemiological data, good evidence for the accuracy of diagnosis of maternal CMV infection and good evidence for the feasibility of predicting the outcome of fetal infection by a combination of fetal imaging and fetal laboratory parameters. There is also some evidence that valaciclovir treatment of mothers carrying an infected fetus is feasible, safe and might be effective. This review provides an update on the evidence for diagnosis, prognosis and treatment of congenital infection in the antenatal period. These suggest a benefit to a proactive approach for prenatal congenital infections. Cytomegalovirus (CMV) congenital infection affects 0.7% of live births worldwide and is the leading cause of congenital neurological handicap of infectious origin. However, systematic screening for this infection has not been implemented in pregnancy or at birth in any country. This apparent paradox had been justified by persisting gaps in the knowledge of this congenital infection: uncertain epidemiological data, difficulty in the diagnosis of maternal infection, absence of validated prenatal prognostic markers, unavailability of an efficient vaccine and scarcity of data available on the treatment. However, in the last decade, new data have emerged towards better management of this congenital infection, including solid epidemiological data, good evidence for the accuracy of diagnosis of maternal CMV infection and good evidence for the feasibility of predicting the outcome of fetal infection by a combination of fetal imaging and fetal laboratory parameters. There is also some evidence that valaciclovir treatment of mothers carrying an infected fetus is feasible, safe and might be effective. This review provides an update on the evidence for diagnosis, prognosis and treatment of congenital infection in the antenatal period. These suggest a benefit to a proactive approach for prenatal congenital infections. hyperimmune globulin Elsevier valaciclovir Elsevier cytomegalovirus Elsevier serology Elsevier imaging Elsevier fetus Elsevier Ville, Yves oth Enthalten in Harcourt In vitro and in vivo quality of bovine embryos in vitro produced with sex-sorted sperm 2012transfer abstract London [u.a.] (DE-627)ELV026204967 volume:38 year:2017 pages:97-107 extent:11 https://doi.org/10.1016/j.bpobgyn.2016.10.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-LING SSG-OPC-BBI GBV_ILN_50 GBV_ILN_72 GBV_ILN_1003 54.00 Informatik: Allgemeines VZ 53.71 Theoretische Nachrichtentechnik VZ AR 38 2017 97-107 11 045F 610 |
| allfieldsSound |
10.1016/j.bpobgyn.2016.10.005 doi GBVA2017004000002.pica (DE-627)ELV040287688 (ELSEVIER)S1521-6934(16)30109-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 590 VZ 070 004 VZ LING DE-30 fid 54.00 bkl 53.71 bkl Leruez-Ville, Marianne verfasserin aut Fetal cytomegalovirus infection 2017transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Cytomegalovirus (CMV) congenital infection affects 0.7% of live births worldwide and is the leading cause of congenital neurological handicap of infectious origin. However, systematic screening for this infection has not been implemented in pregnancy or at birth in any country. This apparent paradox had been justified by persisting gaps in the knowledge of this congenital infection: uncertain epidemiological data, difficulty in the diagnosis of maternal infection, absence of validated prenatal prognostic markers, unavailability of an efficient vaccine and scarcity of data available on the treatment. However, in the last decade, new data have emerged towards better management of this congenital infection, including solid epidemiological data, good evidence for the accuracy of diagnosis of maternal CMV infection and good evidence for the feasibility of predicting the outcome of fetal infection by a combination of fetal imaging and fetal laboratory parameters. There is also some evidence that valaciclovir treatment of mothers carrying an infected fetus is feasible, safe and might be effective. This review provides an update on the evidence for diagnosis, prognosis and treatment of congenital infection in the antenatal period. These suggest a benefit to a proactive approach for prenatal congenital infections. Cytomegalovirus (CMV) congenital infection affects 0.7% of live births worldwide and is the leading cause of congenital neurological handicap of infectious origin. However, systematic screening for this infection has not been implemented in pregnancy or at birth in any country. This apparent paradox had been justified by persisting gaps in the knowledge of this congenital infection: uncertain epidemiological data, difficulty in the diagnosis of maternal infection, absence of validated prenatal prognostic markers, unavailability of an efficient vaccine and scarcity of data available on the treatment. However, in the last decade, new data have emerged towards better management of this congenital infection, including solid epidemiological data, good evidence for the accuracy of diagnosis of maternal CMV infection and good evidence for the feasibility of predicting the outcome of fetal infection by a combination of fetal imaging and fetal laboratory parameters. There is also some evidence that valaciclovir treatment of mothers carrying an infected fetus is feasible, safe and might be effective. This review provides an update on the evidence for diagnosis, prognosis and treatment of congenital infection in the antenatal period. These suggest a benefit to a proactive approach for prenatal congenital infections. hyperimmune globulin Elsevier valaciclovir Elsevier cytomegalovirus Elsevier serology Elsevier imaging Elsevier fetus Elsevier Ville, Yves oth Enthalten in Harcourt In vitro and in vivo quality of bovine embryos in vitro produced with sex-sorted sperm 2012transfer abstract London [u.a.] (DE-627)ELV026204967 volume:38 year:2017 pages:97-107 extent:11 https://doi.org/10.1016/j.bpobgyn.2016.10.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-LING SSG-OPC-BBI GBV_ILN_50 GBV_ILN_72 GBV_ILN_1003 54.00 Informatik: Allgemeines VZ 53.71 Theoretische Nachrichtentechnik VZ AR 38 2017 97-107 11 045F 610 |
| language |
English |
| source |
Enthalten in In vitro and in vivo quality of bovine embryos in vitro produced with sex-sorted sperm London [u.a.] volume:38 year:2017 pages:97-107 extent:11 |
| sourceStr |
Enthalten in In vitro and in vivo quality of bovine embryos in vitro produced with sex-sorted sperm London [u.a.] volume:38 year:2017 pages:97-107 extent:11 |
| format_phy_str_mv |
Article |
| bklname |
Informatik: Allgemeines Theoretische Nachrichtentechnik |
| institution |
findex.gbv.de |
| topic_facet |
hyperimmune globulin valaciclovir cytomegalovirus serology imaging fetus |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
In vitro and in vivo quality of bovine embryos in vitro produced with sex-sorted sperm |
| authorswithroles_txt_mv |
Leruez-Ville, Marianne @@aut@@ Ville, Yves @@oth@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
ELV026204967 |
| dewey-sort |
3610 |
| id |
ELV040287688 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV040287688</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625231424.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.bpobgyn.2016.10.005</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017004000002.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV040287688</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1521-6934(16)30109-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">590</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">070</subfield><subfield code="a">004</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">LING</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">54.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">53.71</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Leruez-Ville, Marianne</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Fetal cytomegalovirus infection</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">11</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cytomegalovirus (CMV) congenital infection affects 0.7% of live births worldwide and is the leading cause of congenital neurological handicap of infectious origin. However, systematic screening for this infection has not been implemented in pregnancy or at birth in any country. This apparent paradox had been justified by persisting gaps in the knowledge of this congenital infection: uncertain epidemiological data, difficulty in the diagnosis of maternal infection, absence of validated prenatal prognostic markers, unavailability of an efficient vaccine and scarcity of data available on the treatment. However, in the last decade, new data have emerged towards better management of this congenital infection, including solid epidemiological data, good evidence for the accuracy of diagnosis of maternal CMV infection and good evidence for the feasibility of predicting the outcome of fetal infection by a combination of fetal imaging and fetal laboratory parameters. There is also some evidence that valaciclovir treatment of mothers carrying an infected fetus is feasible, safe and might be effective. This review provides an update on the evidence for diagnosis, prognosis and treatment of congenital infection in the antenatal period. These suggest a benefit to a proactive approach for prenatal congenital infections.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cytomegalovirus (CMV) congenital infection affects 0.7% of live births worldwide and is the leading cause of congenital neurological handicap of infectious origin. However, systematic screening for this infection has not been implemented in pregnancy or at birth in any country. This apparent paradox had been justified by persisting gaps in the knowledge of this congenital infection: uncertain epidemiological data, difficulty in the diagnosis of maternal infection, absence of validated prenatal prognostic markers, unavailability of an efficient vaccine and scarcity of data available on the treatment. However, in the last decade, new data have emerged towards better management of this congenital infection, including solid epidemiological data, good evidence for the accuracy of diagnosis of maternal CMV infection and good evidence for the feasibility of predicting the outcome of fetal infection by a combination of fetal imaging and fetal laboratory parameters. There is also some evidence that valaciclovir treatment of mothers carrying an infected fetus is feasible, safe and might be effective. This review provides an update on the evidence for diagnosis, prognosis and treatment of congenital infection in the antenatal period. These suggest a benefit to a proactive approach for prenatal congenital infections.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">hyperimmune globulin</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">valaciclovir</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">cytomegalovirus</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">serology</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">imaging</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">fetus</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ville, Yves</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Harcourt</subfield><subfield code="t">In vitro and in vivo quality of bovine embryos in vitro produced with sex-sorted sperm</subfield><subfield code="d">2012transfer abstract</subfield><subfield code="g">London [u.a.]</subfield><subfield code="w">(DE-627)ELV026204967</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:38</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:97-107</subfield><subfield code="g">extent:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.bpobgyn.2016.10.005</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-LING</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-BBI</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_50</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_72</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_1003</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">54.00</subfield><subfield code="j">Informatik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">53.71</subfield><subfield code="j">Theoretische Nachrichtentechnik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">38</subfield><subfield code="j">2017</subfield><subfield code="h">97-107</subfield><subfield code="g">11</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Leruez-Ville, Marianne |
| spellingShingle |
Leruez-Ville, Marianne ddc 610 ddc 590 ddc 070 fid LING bkl 54.00 bkl 53.71 Elsevier hyperimmune globulin Elsevier valaciclovir Elsevier cytomegalovirus Elsevier serology Elsevier imaging Elsevier fetus Fetal cytomegalovirus infection |
| authorStr |
Leruez-Ville, Marianne |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV026204967 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 590 - Animals (Zoology) 070 - News media, journalism & publishing 004 - Data processing & computer science |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 590 VZ 070 004 VZ LING DE-30 fid 54.00 bkl 53.71 bkl Fetal cytomegalovirus infection hyperimmune globulin Elsevier valaciclovir Elsevier cytomegalovirus Elsevier serology Elsevier imaging Elsevier fetus Elsevier |
| topic |
ddc 610 ddc 590 ddc 070 fid LING bkl 54.00 bkl 53.71 Elsevier hyperimmune globulin Elsevier valaciclovir Elsevier cytomegalovirus Elsevier serology Elsevier imaging Elsevier fetus |
| topic_unstemmed |
ddc 610 ddc 590 ddc 070 fid LING bkl 54.00 bkl 53.71 Elsevier hyperimmune globulin Elsevier valaciclovir Elsevier cytomegalovirus Elsevier serology Elsevier imaging Elsevier fetus |
| topic_browse |
ddc 610 ddc 590 ddc 070 fid LING bkl 54.00 bkl 53.71 Elsevier hyperimmune globulin Elsevier valaciclovir Elsevier cytomegalovirus Elsevier serology Elsevier imaging Elsevier fetus |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
y v yv |
| hierarchy_parent_title |
In vitro and in vivo quality of bovine embryos in vitro produced with sex-sorted sperm |
| hierarchy_parent_id |
ELV026204967 |
| dewey-tens |
610 - Medicine & health 590 - Animals (Zoology) 070 - News media, journalism & publishing 000 - Computer science, knowledge & systems |
| hierarchy_top_title |
In vitro and in vivo quality of bovine embryos in vitro produced with sex-sorted sperm |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV026204967 |
| title |
Fetal cytomegalovirus infection |
| ctrlnum |
(DE-627)ELV040287688 (ELSEVIER)S1521-6934(16)30109-2 |
| title_full |
Fetal cytomegalovirus infection |
| author_sort |
Leruez-Ville, Marianne |
| journal |
In vitro and in vivo quality of bovine embryos in vitro produced with sex-sorted sperm |
| journalStr |
In vitro and in vivo quality of bovine embryos in vitro produced with sex-sorted sperm |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science 000 - Computer science, information & general works |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
97 |
| author_browse |
Leruez-Ville, Marianne |
| container_volume |
38 |
| physical |
11 |
| class |
610 610 DE-600 590 VZ 070 004 VZ LING DE-30 fid 54.00 bkl 53.71 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Leruez-Ville, Marianne |
| doi_str_mv |
10.1016/j.bpobgyn.2016.10.005 |
| dewey-full |
610 590 070 004 |
| title_sort |
fetal cytomegalovirus infection |
| title_auth |
Fetal cytomegalovirus infection |
| abstract |
Cytomegalovirus (CMV) congenital infection affects 0.7% of live births worldwide and is the leading cause of congenital neurological handicap of infectious origin. However, systematic screening for this infection has not been implemented in pregnancy or at birth in any country. This apparent paradox had been justified by persisting gaps in the knowledge of this congenital infection: uncertain epidemiological data, difficulty in the diagnosis of maternal infection, absence of validated prenatal prognostic markers, unavailability of an efficient vaccine and scarcity of data available on the treatment. However, in the last decade, new data have emerged towards better management of this congenital infection, including solid epidemiological data, good evidence for the accuracy of diagnosis of maternal CMV infection and good evidence for the feasibility of predicting the outcome of fetal infection by a combination of fetal imaging and fetal laboratory parameters. There is also some evidence that valaciclovir treatment of mothers carrying an infected fetus is feasible, safe and might be effective. This review provides an update on the evidence for diagnosis, prognosis and treatment of congenital infection in the antenatal period. These suggest a benefit to a proactive approach for prenatal congenital infections. |
| abstractGer |
Cytomegalovirus (CMV) congenital infection affects 0.7% of live births worldwide and is the leading cause of congenital neurological handicap of infectious origin. However, systematic screening for this infection has not been implemented in pregnancy or at birth in any country. This apparent paradox had been justified by persisting gaps in the knowledge of this congenital infection: uncertain epidemiological data, difficulty in the diagnosis of maternal infection, absence of validated prenatal prognostic markers, unavailability of an efficient vaccine and scarcity of data available on the treatment. However, in the last decade, new data have emerged towards better management of this congenital infection, including solid epidemiological data, good evidence for the accuracy of diagnosis of maternal CMV infection and good evidence for the feasibility of predicting the outcome of fetal infection by a combination of fetal imaging and fetal laboratory parameters. There is also some evidence that valaciclovir treatment of mothers carrying an infected fetus is feasible, safe and might be effective. This review provides an update on the evidence for diagnosis, prognosis and treatment of congenital infection in the antenatal period. These suggest a benefit to a proactive approach for prenatal congenital infections. |
| abstract_unstemmed |
Cytomegalovirus (CMV) congenital infection affects 0.7% of live births worldwide and is the leading cause of congenital neurological handicap of infectious origin. However, systematic screening for this infection has not been implemented in pregnancy or at birth in any country. This apparent paradox had been justified by persisting gaps in the knowledge of this congenital infection: uncertain epidemiological data, difficulty in the diagnosis of maternal infection, absence of validated prenatal prognostic markers, unavailability of an efficient vaccine and scarcity of data available on the treatment. However, in the last decade, new data have emerged towards better management of this congenital infection, including solid epidemiological data, good evidence for the accuracy of diagnosis of maternal CMV infection and good evidence for the feasibility of predicting the outcome of fetal infection by a combination of fetal imaging and fetal laboratory parameters. There is also some evidence that valaciclovir treatment of mothers carrying an infected fetus is feasible, safe and might be effective. This review provides an update on the evidence for diagnosis, prognosis and treatment of congenital infection in the antenatal period. These suggest a benefit to a proactive approach for prenatal congenital infections. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-LING SSG-OPC-BBI GBV_ILN_50 GBV_ILN_72 GBV_ILN_1003 |
| title_short |
Fetal cytomegalovirus infection |
| url |
https://doi.org/10.1016/j.bpobgyn.2016.10.005 |
| remote_bool |
true |
| author2 |
Ville, Yves |
| author2Str |
Ville, Yves |
| ppnlink |
ELV026204967 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth |
| doi_str |
10.1016/j.bpobgyn.2016.10.005 |
| up_date |
2024-07-06T17:07:03.760Z |
| _version_ |
1803850218220814336 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV040287688</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625231424.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.bpobgyn.2016.10.005</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017004000002.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV040287688</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1521-6934(16)30109-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">590</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">070</subfield><subfield code="a">004</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">LING</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">54.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">53.71</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Leruez-Ville, Marianne</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Fetal cytomegalovirus infection</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">11</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cytomegalovirus (CMV) congenital infection affects 0.7% of live births worldwide and is the leading cause of congenital neurological handicap of infectious origin. However, systematic screening for this infection has not been implemented in pregnancy or at birth in any country. This apparent paradox had been justified by persisting gaps in the knowledge of this congenital infection: uncertain epidemiological data, difficulty in the diagnosis of maternal infection, absence of validated prenatal prognostic markers, unavailability of an efficient vaccine and scarcity of data available on the treatment. However, in the last decade, new data have emerged towards better management of this congenital infection, including solid epidemiological data, good evidence for the accuracy of diagnosis of maternal CMV infection and good evidence for the feasibility of predicting the outcome of fetal infection by a combination of fetal imaging and fetal laboratory parameters. There is also some evidence that valaciclovir treatment of mothers carrying an infected fetus is feasible, safe and might be effective. This review provides an update on the evidence for diagnosis, prognosis and treatment of congenital infection in the antenatal period. These suggest a benefit to a proactive approach for prenatal congenital infections.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cytomegalovirus (CMV) congenital infection affects 0.7% of live births worldwide and is the leading cause of congenital neurological handicap of infectious origin. However, systematic screening for this infection has not been implemented in pregnancy or at birth in any country. This apparent paradox had been justified by persisting gaps in the knowledge of this congenital infection: uncertain epidemiological data, difficulty in the diagnosis of maternal infection, absence of validated prenatal prognostic markers, unavailability of an efficient vaccine and scarcity of data available on the treatment. However, in the last decade, new data have emerged towards better management of this congenital infection, including solid epidemiological data, good evidence for the accuracy of diagnosis of maternal CMV infection and good evidence for the feasibility of predicting the outcome of fetal infection by a combination of fetal imaging and fetal laboratory parameters. There is also some evidence that valaciclovir treatment of mothers carrying an infected fetus is feasible, safe and might be effective. This review provides an update on the evidence for diagnosis, prognosis and treatment of congenital infection in the antenatal period. These suggest a benefit to a proactive approach for prenatal congenital infections.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">hyperimmune globulin</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">valaciclovir</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">cytomegalovirus</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">serology</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">imaging</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">fetus</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ville, Yves</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Harcourt</subfield><subfield code="t">In vitro and in vivo quality of bovine embryos in vitro produced with sex-sorted sperm</subfield><subfield code="d">2012transfer abstract</subfield><subfield code="g">London [u.a.]</subfield><subfield code="w">(DE-627)ELV026204967</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:38</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:97-107</subfield><subfield code="g">extent:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.bpobgyn.2016.10.005</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-LING</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-BBI</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_50</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_72</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_1003</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">54.00</subfield><subfield code="j">Informatik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">53.71</subfield><subfield code="j">Theoretische Nachrichtentechnik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">38</subfield><subfield code="j">2017</subfield><subfield code="h">97-107</subfield><subfield code="g">11</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.3985004 |